Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities
Goldie Y.L. Lui(Fred Hutch Cancer Center), Carla Grandori(Precision for Medicine (United States)), Mia Lints(Precision for Medicine (United States)), Isabella N. Stork(Fred Hutch Cancer Center), Madison Pollastro, Lauren Appleyard(Precision for Medicine (United States)), Anne B. Richardson(Precision for Medicine (United States)), Hallie A. Swan(Precision for Medicine (United States)), Kay E. Gurley(Fred Hutch Cancer Center), Heidi J. Gray(Seattle Cancer Care Alliance), Kalyan Banda(University of Washington), Barbara A. Goff(University of Washington), Yasin Memari(Wellcome Sanger Institute), D. Peretti(Precision for Medicine (United States)), Serena Nik‐Zainal(University of Cambridge), Helen Davies(German Cancer Research Center), Payel Chatterjee(Precision for Medicine (United States)), Rachele Rosati(Precision for Medicine (United States)), Elizabeth M. Swisher(University of Washington), Grace Durenberger(Precision for Medicine (United States)), Astrid Margossian(Precision for Medicine (United States)), Christopher J. Kemp(Fred Hutch Cancer Center), Adam Whitney(Brigham and Women's Hospital), Robert L. Diaz, Katannya Kapeli(University of California, San Diego)
Cited by 4
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k